Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...

In some cases, incentives designed to drive adoption could even push stablecoins into riskier territory, encouraging people to treat them more like speculative assets than money. New research from the ...

This study offers a valuable advance for neuroscience by extending a visualization tool that enables intuitive assessment of how dendritic and synaptic currents shape the output of neurons. The ...

But stablecoin's future might hinge on whether it becomes mainstream digital money for low-cost payments or a tool for a growing universe of risky leveraged finance. For widespread stablecoin adoption ...

Microsoft Azure has been experiencing a global outage since around 1600 UTC, or 0900 PDT on Wednesday, October 29, 2025. As Azure staggers back to its feet following an hours-long outage last night, ...

From designing proteins not found in nature to extending healthy lifespan, Retro Biosciences is applying AI models to advance cellular reprogramming for aging research. The company operates across ...

Virtual screening methods fall broadly into two categories: ligand- and structure-based. Ligand-based virtual screening doesn’t require a target protein structure, Instead, it leverages known active ...

Labor markets in Central America and the Dominican Republic face limited direct impacts from technological advancements ...

Effective monitoring of development aid is the foundation for assessing the alignment of flows with their intended ...